Open AccessThe use of ranolazine in the treatment of coronary heart disease
Author(s) -
В. С. Задионченко,
Задионченко Владимир Семенович,
G. G Shehyan,
Шехян Грант Георгиевич,
A. A Yalymov,
Ялымов Анатолий Александрович,
С. И. Варенцов,
Варенцов Сергей Игоревич
Publication year - 2014
Publication title -
cardiosomatika
Language(s) - English
Resource type - Journals
eISSN - 2658-5707
pISSN - 2221-7185
DOI - 10.26442/cs45130
Subject(s) - ranolazine , medicine , angina , cardiology , coronary heart disease , drug , coronary artery disease , clinical trial , pharmacology , myocardial infarction
The paper presents the study of a new anti-anginal drug - sodium channel inhibitor ranolazine. Considered antianginal, anti-ischemic effect of the drug. Described reduction in angina attacks, increased exercise tolerance and quality of life of patients with stable angina during treatment with ranolazine. Discusses indications, contraindications, side effects, as well as the major clinical trials of the drug ranolazine in patients with coronary heart disease.